Alacrity BioSciences
Alacrity Biosciences, Inc., a biopharmaceutical company focused on meeting unmet needs in ophthalmic diseases, today announced that clinical data from an independent pilot study using 0.025% doxycycline eye drops to treat dry eye patients in the Controlled Adverse Environment model will be presented at the Association for Research and Vision in Ophthalmology (ARVO) Meeting.
The study was conducted by Ophthalmic Research Associates of North Andover, MA under a grant provided by Alacrity Biosciences. The ARVO Meeting takes place May 6-10, 2007 at the Greater Fort Lauderdale/Broward County Convention Center in Fort Lauderdale, Florida.
"We are highly encouraged that this pilot study appears to validate the premise that use of topical doxycycline can maintain the integrity of the corneal epithelial barrier in dry eye patients using the Controlled Adverse Environment (CAE) model," said David F. Power, President and CEO of Alacrity Biosciences, Inc.
Information related to the presentation is as follows:
About Alacrity Biosciences
Alacrity Biosciences, Inc. is a Laguna Hills-based biopharmaceutical company focused on acquiring, developing and commercializing innovative therapeutics to treat ophthalmic diseases that threaten vision and reduce patient quality of life. For additional information visit www.alacritybio.com.
The Alacrity Biosciences logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3419